4/17
01:17 pm
nbix
Rating for NBIX
Low
Report
Rating for NBIX
4/17
01:17 pm
nbix
Rating for NBIX
Low
Report
Rating for NBIX
4/10
10:19 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
4/10
09:44 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
3/20
08:03 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
3/13
08:37 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
3/13
08:37 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/23
12:40 pm
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/8
11:24 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/8
11:24 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/8
10:28 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/8
10:28 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/8
08:41 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
2/8
08:41 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
1/25
09:15 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
1/25
09:15 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX
1/25
09:15 am
nbix
Rating for NBIX
Low
Report
Rating for NBIX